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safety and performance of the Absorb BVS in a larger population of patients, including
those with longer lesions and dual vessel treatment. Clinical composites and component
end points will be presented out to 12 months.
Conclusions: Clinical and angiographic outcomes from the First-in-Man ABSORB trial
have demonstrated the safety and efficacy of the Absorb BVS in lesions 14 mm. Interim
outcomes in 250 patients at 12 months, (the largest patient cohort reported at this time
point to date) from ABSORB EXTEND will provide further insight into the longer-term
safety and efficacy of the ABSORB BVS in patients with longer lesions.
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Background: The ABSORB Cohort A trial results demonstrated the safety of Absorb
BVS (Abbott Vascular, Santa Clara, CA, USA) in 30 patients with single de novo native
coronary artery lesions, with a low long-term MACE rate at 5 years (3.4%) and no
scaffold thrombosis. The ABSORB Cohort B trial, a continuation of that assessment with
a modified Absorb BVS, enrolled 101 patients at 12 sites in European and Asia Pacific
regions between March and November 2009.
Methods: The patients of the ABSORB Cohort B trial were divided into 2 groups, Cohort
B1 (45 patients, enrolment from March 19 to August 20, 2009) having angiographic
follow-up performed at 180 days and 2 years and Cohort B2 (56 patients, enrolment from
August 21 to November 6, 2009) having angiographic follow-up performed at 1 and 3
years. Key clinical endpoints include ischemia driven MACE (ID-MACE) and its
components at 30 days, 6, 9 and 18 months, and 1, 2, 3, 4 and 5 years.
Results: In Cohort B, clinical data up to 2 years for the full cohort of 101 patients (Group
B1 and B2) are currently available and are summarized hereafter. The mean age was 62
years, 72% of patients were male, 17% of patients were current tobacco users. Patients
with diabetes: 17%, hypertension: 66%, hypercholesterolemia: 85%, family history of
CAD: 55%, stable angina: 68%, of which15% having stable angina with CCS classifi-
cation of III or IV. Patients with unstable angina: 15%, 2% with unstable angina of
Braunwald Class III. Lesion location was RCA (33%), LAD (43%), LCX (22%) and
Ramus (1%), with ACC/AHA lesion classification of A for 1% of patients, B1 for 55%,
B2 for 40% and C for 4%. In these 101 patients, 2 year results showed an ID-MACE rate
of 9.0% and no scaffold thrombosis. The angiographic results for Cohort B1 demonstrated
an angiographic late loss at 180 days of 0.19 mm and at 2 years of 0.27 mm. This value
of 0.27 mm at 2 years was similar to the late loss in Cohort B2 at 1 year (0.27 mm).The
3-year clinical results for Cohort B1 will be presented. Clinical and imaging results at
3-year for all patients in Cohort B will be available in 2013.
Conclusions: Three year clinical follow-up data of Cohort B1 is pending.
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Background: Recent reports have demonstrated that the healing process after the
deployment of a bioresorbable scaffold (BRS) leads to the development of fibromuscular
tissue that covers the vessel wall. However the distribution of the neointima over the
vessel wall remains unclear. In this study we evaluated the circumferential distribution of
the neointima tissue developed after a BRS implantation at 6 months and at 2 years
follow-up.
Methods: We analyzed data from 20 patients who had undergone an Abbott Vascular
BRS 1.1 implantation and have been investigated with optical coherence tomography
(OCT) at baseline, immediate after scaffold implantation, at 6 months and at 2 years
follow-up. In the acquired sequences an experienced operator detected the luminal and the
scaffold borders and then the circumferential thickness of the neointima was measured at
1 degree interval with the use of dedicated software. The symmetry of the neointima tissue
was defined as the ratio minimum/maximum neointima thickness.
Results: The lumen area decreased at 6 months but there was no difference between the
2 follow-up time points [7.56 (6.37-7.98)mm2 vs. 6.28 (4.89-7.05)mm2 at 6 months,
P0.001; vs. 6.06 (5.01-7.11)mm2 at 2 years, P0.851]. The mean neointima thickness
was increased at 2 years [192 (174-232) m vs. 254 (230-288) m, P0.0001] and the
symmetry index of the neointima was higher [0.06 (0.02-0.09) vs. 0.27 (0.24-0.34),
P0.0001] at this time point suggesting a more homogenous distribution. Full circum-
ferential coverage of the vessel wall by neointima tissue was seen in 90% of the studied
frames, at 2 years. In 79% of the analyzed frames the minimum neointima thickness was
65m at this time point.
Conclusions: We analyzed, for the first time serial OCT data, to investigate the
neointima evolution and its circumferential distribution after a BRS implantation. It was
found that a thick neointima tissue develops which at 2 years covers, in most of the
frames, the whole circumference of the vessel wall. Hence, the Abbott Vascular BRS 1.1
can be regarded as a potentially useful device for the passivation of high risk plaques.
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Background: Multimodality imaging of the first-in-man trial using fully resorbable
everolimus-eluting scaffold (BVS, Abbott Vascular, Santa Clara, USA) demonstrated at 2
years the bioresorption of the device while preventing restenosis. Nevertheless, the
long-term safety and efficacy of this therapy remain to be documented.
Methods: In the ABSORB cohort A trial, 30 patients with a single de novo coronary
artery lesion were treated with the fully resorbable everolimus-eluting ABSORB scaffold
(Abbott vascular, CA, US). The patients underwent MSCT imaging at 5 years. Acquired
MSCT data was analyzed in an independent corelab (Cardialysis, Netherlands) for
quantitative analysis of lumen dimensions, and was further processed for calculation of
fractional flow reserve in another independent corelab (Heart Flow, CA, USA).
Results: Five-year clinical follow-up is available in 29 patients since one patient
withdrew consent after 6 months. At 46 days, one patient experienced a single episode of
chest pain and underwent a target lesion revascularization with slight troponin rise after
the procedure. At 5 years, the ID-MACE of 3.4% remained unchanged. Clopidogrel was
discontinued in all but one patient. There has been no stent thrombosis reported. Two
non-cardiac deaths were reported; one from duodenal perforation, the other from
Hodgkin’s disease. At 5 years, 18 patients underwent MSCT scan. All scaffolds were
patent with an average minimal lumen area of 3.41.4 mm2 with an average area stenosis
of 2923%. Out of 18 cases, non-invasive FFR analysis was feasible in 13 cases. The
median of FFR-CT in the distal segment was 0.83 [interquartile range: 0.81, 0.94].
Conclusions: Five-year clinical results have demonstrated a sustained low MACE rate
without any late complication such as stent thrombosis. MSCT assessment was feasible
after placement of Bioresorbable scaffold and non-invasive FFR can be also assessed in
the selected cases.
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Background: In order to assess the intermediate term safety, clinical performance and
the bioabsorption process of the Paclitaxel-Eluting Bioabsorbable Magnesium Scaffold
(DREAMS) 2-year clinical data of cohort 1 and multi-modality imaging outcomes up to
1 year follow-up are reported.
Methods: Forty-six subjects were enrolled in the first-in-man BIOSOLVE-I study, and
assigned to two different cohorts with different invasive follow-up schedules. Clinical
follow-up for both cohorts is scheduled at 1, 6, 12, 24 and 36 months, angiographic and
IVUS follow-up for cohort 1 at 6 months and for cohort 2 at 12 months. A subgroup of
patients underwent OCT and vasomotion testing. The primary endpoint is Target Lesion
Failure (TLF), defined as the composite of cardiac death, target vessel myocardial
infarction and clinically driven target lesion failure, at 6 months for cohort 1 and at 12
month for cohort 2.
Results: Clinical: TLF rate at 12-month was 7.0% including two clinically driven target
lesion revascularizations and one peri-procedural target vessel myocardial infarction
occurring during 12-month follow-up angiography. No cardiac death or scaffold throm-
bosis was observed. Twenty-four month clinical data of cohort 1 will be available upon
presentation. Angiographic: In-scaffold late lumen loss was 0.520.39 at 12 months.
Vasoconstriction after acetylcholine was documented by quantitative coronary angiogra-
phy (delta-10.04%; p0.0008) followed by vasodilatation after nitroglycerine
(delta8.69%; p0.0001) which demonstrates the uncaging aspect of the absorption
process already at 6-month follow-up with no further change at the 12-month follow-up.
IVUS: Six-month virtual histology (VH) data showed a significant decrease in the dense
calcium by 39.5% (p0.0015) which remains stable until 12-month follow-up. This
decrease of dense calcium is interpreted as a surrogate assessment for the bioabsorption
process of the scaffold material.
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